The Plasma Protein Therapeutics Association (PPTA) is a dynamic trade association that represents a unique sector of the biologics and biotechnology industry. PPTA represents more than 1,000 human plasma collection centers in North America and Europe, as well as the manufacturers of lifesaving plasma protein therapies. Our members produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
- Advocate for patient access to plasma-derived medicines
- Responsibly improve the reliable availability of plasma
- Advance the understanding of the plasma ecosystem
PPTA also administers standards programs that help ensure the quality and safety of plasma collection and manufacturing and protect both donors and patients.
- International Quality Plasma Program (IQPP)
- Quality Standards of Excellence, Assurance and Leadership (QSEAL)
- National Donor Deferral Registry (NDDR®)
- Patient Notification System (PNS)
- North America Data Program
- European Distribution Data
As a trusted partner to health systems, PPTA drives broad and reliable access to high-quality plasma protein therapies, with a focus on the well-being of patients and plasma donors. We will strive to achieve our mission by:
- Fostering the collection of high-quality plasma from healthy donors;
- Establishing standards for the manufacturing of lifesaving plasma protein therapies at the highest levels of safety and quality;
- Breaking down artificial barriers on trade and compensated donors that limit patient access to therapy;
- Supporting government reimbursement practices that reflect the unique nature of plasma protein therapies;
- Educating all stakeholders about the value of the therapies; and
- Adhering to the PPTA Code of Ethics.
PPTA annually publishes a comprehensive report on Association activities throughout the preceding year.